Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid.
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis; D015153:Blotting, Western; D042846:CDC2-CDC28 Kinases / Q000378:metabolism; D002453:Cell Cycle; D002455:Cell Division; D045744:Cell Line, Tumor; D019938:Cyclin D1 / Q000378:metabolism; D051357:Cyclin-Dependent Kinase 2; D051358:Cyclin-Dependent Kinase 4; D051361:Cyclin-Dependent Kinase 6; D018844:Cyclin-Dependent Kinases / Q000378:metabolism; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D016898:Interferon-alpha / Q000378:metabolism / Q000494:pharmacology; D007371:Interferon-gamma / Q000378:metabolism / Q000494:pharmacology; D008024:Ligands; D010190:Pancreatic Neoplasms / Q000378:metabolism; D010957:Plasmids / Q000378:metabolism; D011485:Protein Binding; D011518:Proto-Oncogene Proteins; D018168:Receptors, Retinoic Acid / Q000378:metabolism*; D047488:Retinoid X Receptors; D012176:Retinoids / Q000378:metabolism*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology*; D013997:Time Factors; D014157:Transcription Factors / Q000378:metabolism*; D000093542:Gemcitabine
C430898:AGN 194204; D000964:Antimetabolites, Antineoplastic; D005231:Fatty Acids, Unsaturated; D016898:Interferon-alpha; D008024:Ligands; D011518:Proto-Oncogene Proteins; D018168:Receptors, Retinoic Acid; D047488:Retinoid X Receptors; D012176:Retinoids; D013764:Tetrahydronaphthalenes; D014157:Transcription Factors; D003841:Deoxycytidine; D019938:Cyclin D1; D007371:Interferon-gamma; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; C495900:CDK4 protein, human; C495911:CDK6 protein, human; D051357:Cyclin-Dependent Kinase 2; D051358:Cyclin-Dependent Kinase 4; D051361:Cyclin-Dependent Kinase 6; D018844:Cyclin-Dependent Kinases; D005472:Fluorouracil; D000093542:Gemcitabine